bioMerieux released Q1 FY17 trading results ahead of our estimates as well as market consensus. The revenue at CER increased by 13.7% (vs AV’s estimate: +9.5%), driven by strong growth momentum in the clinical applications segment (+14.7% vs AV’s estimate: +9.7%; accounts for c.81% of Q1 17 sales). Within the segment, the key growth contributor was the molecular biology business (+43.4% vs AV’s estimate: +30%; accounts for c.21% of Q1 17 sales), led by a stellar performance
27 Apr 2017
Strong Q1 results; FilmArray continues to be the bright spot
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 results; FilmArray continues to be the bright spot
bioMerieux released Q1 FY17 trading results ahead of our estimates as well as market consensus. The revenue at CER increased by 13.7% (vs AV’s estimate: +9.5%), driven by strong growth momentum in the clinical applications segment (+14.7% vs AV’s estimate: +9.7%; accounts for c.81% of Q1 17 sales). Within the segment, the key growth contributor was the molecular biology business (+43.4% vs AV’s estimate: +30%; accounts for c.21% of Q1 17 sales), led by a stellar performance